Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
Status:
Recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This is a randomized double-blind controlled exploratory clinical study to evaluate the
efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS)
patients.